A comparison of sibutramine and
dexfenfluramine in the treatment of obesity

by
Hanotin C, Thomas F, Jones SP,
Leutenegger E, Drouin P.
Medical Direction,
Laboratoires Knoll France-BASF Pharma,
Levallois-Perret, France.
Obes Res 1998 Jul; 6(4):285-91


ABSTRACT

OBJECTIVE: Because long-term weight reduction is often unsuccessful with dietary restriction alone, pharmacological agents have been used to promote weight loss. We have compared the novel (multiple monoamine neurotransmitter reuptake inhibitor) antiobesity drug sibutramine (10 mg once daily) with the extensively studied serotonin-releasing antiobesity agent dexfenfluramine (15 mg twice daily). RESEARCH METHODS AND PROCEDURES: 226 healthy outpatients (aged 18 to 65 years; body mass index > or =27 kg/m2) were included in a 12-week, randomized, double-blind, parallel group study. The main outcome measures were changes in weight, body mass index, waist and hip circumference and ratio, and safety profiles. RESULTS: Mean (+/-SEM) absolute weight loss was 4.5 +/- 0.4 kg in the sibutramine group (n = 112) and 3.2 +/- 0.3 kg in the dexfenfluramine group (n = 112) (endpoint analysis); 4.7 +/- 0.4 kg in the sibutramine group (n = 101); and 3.6 +/- 0.3 kg in the dexfenfluramine group (n = 94) (completers analysis). Comparing the two treatments under the conventional null hypothesis of equality as a secondary analysis, weight loss at endpoint in patients receiving sibutramine was significantly greater than that achieved with dexfenfluramine (p<0.05). Both drugs had similar adverse events profiles: 174 patients (77%) experienced adverse events; 17 patients withdrew due to adverse events (sibutramine, n = 6; dexfenfluramine, n = 11). Pulse rate increased significantly in sibutramine-treated patients (3.6 bpm), but decreased in dexfenfluramine-treated patients (-0.9 bpm). DISCUSSION: Sibutramine (10 mg once daily) is at least as effective as dexfenfluramine (15 mg twice daily) in achieving weight loss in patients with obesity.
Fen/Phen
Fluoxetine
Sibutramine
Amphetamines
SSRIs and SNRIs
Sibutramine abuse
New slimming drugs
Beta-adrenoeceptors
Sibutramine compared
Sibutramine and obesity
Alpha-2 adrenoreceptors
Sibutramine for binge-eaters
Sibutramine as an antidepressant
Fenfluramine and dexfenfluramine
Sibutramine, noradrenaline and serotonin
Sibutramine (Meridia): clinical pharmacology
Sibutramine (Meridia): prescribing information (PDF)
Body weight changes associated with psychopharmacology



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family